What to Expect at the 10th Tumor Models Summit San Francisco
Celebrating 10 years of driving innovation in tumor modeling, this landmark anniversary edition delivers our most valuable program yet. A decade of connecting West Coast biopharma pioneers has led to this pivotal moment as the FDA phases out animal toxicity testing requirements and NIH redirects funding, the industry faces its biggest transition toward human-relevant models.
We've curated deeper content than ever on navigating the challenge of modeling immune and non-immune tumor microenvironment components, optimizing model characterization, mastering effective selection strategies for accurate efficacy prediction, maximizing reproducibility, and translating patient heterogeneity into preclinical success.
We're bringing together leaders across preclinical development, translational research, immuno-oncology, in vivo pharmacology, and toxicology for unparalleled cross-functional insights. Don't miss in-depth case studies and strategic roundtables with experts from AbbVie, Amgen, Gilead, Genentech, Bolt Biotherapeutics, 3T Bioscience, and more tackling these challenges for next-generation ADCs, bispecifics, and T-cell engagers.
Unmissable Event Highlights
Debating GEMM Model Utility in Modern Drug Development
Despite their potential for modeling complex genetic tumor drivers, uncertainty remains about real-world GEMM applications. Join Stephanie Casey-Parks, Senior Principal Scientist, Amgen, and Prof. Renu Dhanasekaran, Stanford University, as they tackle when and if GEMMs deserve a place in your pipeline and how to maximize their translational value.
Mastering Tumor Model Variability & Reproducibility
Learn strategies for maximizing model reproducibility and translating patient heterogeneity, including responder vs non-responder profiles with Nadege Morisot, Director In Vivo Translational Biology, Earli Inc., and Prof. Renu Dhanasekaran, Stanford University. Then apply insights in an exclusive mastermind session facilitated by Jessica Orf, Senior Research Scientist II, Gilead Sciences.
Good Laboratory Practice for Non-Animal Safety Testing
As FDA and NIH shift away from animal-only toxicity studies, what does GLP look like for CIVM and alternative models? Barbara Sennino, Senior VP Early Development,
3T Biosciences leads this critical deep dive into balancing regulatory compliance with innovation, ensuring your non-animal safety data meets evolving standards.
Explore the Full Event Guide
- Access the full agenda, speaker lineup, and session topics in one comprehensive document
- Evaluate how each case study and expert-led discussion aligns with your current preclinical work and therapeutic candidates
- Share easily with your colleagues and decision makers to demonstrate value and mobilize attendance
- Discover the leading speakers sharing cutting-edge strategies for effective model selection and preclinical development
Attending Companies Include
Explore the Agenda
Discover cutting-edge model selection strategies from West Coast biopharma and academic pioneers across models like organoids, xenografts, humanized models, and breakthrough modalities.
Partner With Us
Connect your tumor models and preclinical services with biopharma innovators driving the future of oncology drug development.
Join Cross-Modality Leaders
Network with experts in ADCs, bispecifics, degraders, cell therapy, and T-cell engagers advancing model translatability for faster, smarter preclinical pipelines.